Biodesix(us:BDSX)

0.6252

-6.69%

Updated on 2025-03-31

Open:0.6800
Close:0.6252
High:0.6841
Low:0.6252
Prev Close:0.6700
Volume:202505.00
Turnover:130887.09
Turnover Ratio:0.14%
Shares:145.98M
MarketCap:91.27M
DateTotalTotal SharesTotal RatioNewIncreasedDecreased
2024-06-30595343700236.82%181421
2024-03-31471608484416.55%101414
2023-12-31411691437217.58%51314
2023-09-30401712305319.39%11614
2023-06-30341683945921.42%41010
2023-03-31371666457321.37%41113
2022-12-31391605327120.68%12813
2022-09-3041475428011.54%4922
dateorgNametotalratiochangeShareschangeRatio
2024-03-31Birchview Capital, Lp51933365.35%0
2024-03-31Aigh Capital Management Llc33210853.42%-1337861-28.72%
2024-03-31Telemark Asset Management, Llc13260001.36%12500001644.74%
2024-03-31Essex Investment Management Co Llc9256140.95%126691.39%
2024-03-31Wells Fargo & Company/Mn8932030.92%95501.08%
2024-03-31Vanguard Group Inc8079280.83%-3823-0.47%
2024-03-31Opaleye Management Inc.5346570.55%381577.69%
2024-03-31Blackrock Inc.4029080.41%-1553-0.38%
2024-03-31Geode Capital Management, Llc3851450.40%280277.85%
2024-03-31Legato Capital Management Llc3343100.34%0

About

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Boulder, CO.
Address:2970 Wilderness Place,Suite 100

Market Movers